Feb 12 (Reuters) - Merck & Co Inc:
* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AS FIRST-LINE TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
* MERCK - KEYTRUDA PLUS CHEMOTHERAPY SIGNIFICANTLY IMPROVED PFS COMPARED TO CHEMOTHERAPY ALONE IN PATIENTS WITH MTNBC WHOSE TUMORS EXPRESSED PD-L1
* MERCK & CO - SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES
* MERCK - FIRST-LINE TREATMENT WITH KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS
* MERCK & CO INC - NO NEW SAFETY SIGNALS WERE IDENTIFIED IN PHASE 3 STUDY OF KEYTRUDA Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.